MedTrace Logo

Green Subthreshold Laser Therapy for Chronic Central Serous Chorioretinopathy.

NCT07020793 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 12

Last updated 2025-06-13

No results posted yet for this study

Summary

Chronic Central Serous Chorioretinopathy (CSCR) is a vision-threatening retinal disorder characterized by persistent subretinal fluid due to choroidal vascular hyperpermeability and retinal pigment epithelium (RPE) dysfunction. This study evaluates the efficacy and safety of green subthreshold laser therapy using Norlase µSec Technology as a novel, tissue-sparing approach for treating chronic CSCR. By targeting RPE repair without inducing visible retinal damage, this technique aims to resolve subretinal fluid, restore retinal architecture, and improve visual function. This is the first study to report clinical outcomes with this specific laser platform in chronic CSCR management.

Conditions

  • the Presence of Subretinal Fluid (SRF)

Interventions

PROCEDURE

green subthreshold laser therapy

The intervention consists of green subthreshold laser therapy delivered using the Norlase µSec™ Technology, a novel microsecond-pulsed laser platform specifically designed for retinal treatments.

Sponsors & Collaborators

  • Federico II University

    lead OTHER

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-06-01
Primary Completion
2024-06-01
Completion
2025-03-30

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07020793 on ClinicalTrials.gov